Autism biomarkers – not ready for market

Earlier this week, Spectrum News (SFARI as was) carried an interesting and disturbing story about a $2,000 test purporting to identify babies at risk of autism based on an analysis of their placenta.

The test has been trademarked as PlacentASD by Dr Harvey Kliman of the Yale School of Medicine and promoted on the Yale website. In a slick marketing video, Kliman describes the rationale for the test: Continue reading